Assembly Biosciences, Inc. (ASMB)
ASMB Stock Price Chart
Explore Assembly Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze ASMB price movements and trends.
ASMB Company Profile
Discover essential business fundamentals and corporate details for Assembly Biosciences, Inc. (ASMB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Dec 2010
Employees
73.00
Website
https://www.assemblybio.comCEO
Jason A. Okazaki
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
ASMB Financial Timeline
Browse a chronological timeline of Assembly Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.50.
Earnings released on 6 Aug 2025
EPS came in at -$1.33 falling short of the estimated -$0.49 by -171.43%, while revenue for the quarter reached $9.63M , missing expectations by -1.43%.
Earnings released on 8 May 2025
EPS came in at -$1.17 surpassing the estimated -$2.01 by +41.79%, while revenue for the quarter reached $9.42M , beating expectations by +27.03%.
Earnings released on 20 Mar 2025
EPS came in at -$1.57 surpassing the estimated -$1.75 by +10.29%, while revenue for the quarter reached $7.36M , beating expectations by +107.24%.
Earnings released on 7 Nov 2024
EPS came in at -$1.51 surpassing the estimated -$2.02 by +25.25%, while revenue for the quarter reached $6.85M , missing expectations by -2.91%.
Earnings released on 8 Aug 2024
EPS came in at -$1.98 surpassing the estimated -$2.96 by +33.11%, while revenue for the quarter reached $8.53M , beating expectations by +43.17%.
Earnings released on 8 May 2024
EPS came in at -$1.66 surpassing the estimated -$2.74 by +39.42%, while revenue for the quarter reached $5.79M .
Earnings released on 27 Mar 2024
EPS came in at -$2.15 surpassing the estimated -$2.88 by +25.35%, while revenue for the quarter reached $7.16M .
Stock split effective on 12 Feb 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Nov 2023
EPS came in at -$3.24 falling short of the estimated -$2.76 by -17.39%.
Earnings released on 9 Aug 2023
EPS came in at -$3.84 falling short of the estimated -$3.48 by -10.34%.
Earnings released on 4 May 2023
EPS came in at -$4.44 matching the estimated -$4.44.
Earnings released on 22 Mar 2023
EPS came in at -$5.52 surpassing the estimated -$6.72 by +17.86%.
Earnings released on 8 Nov 2022
EPS came in at -$5.76 falling short of the estimated -$5.64 by -2.13%.
Earnings released on 9 Aug 2022
EPS came in at -$6.12 falling short of the estimated -$5.88 by -4.08%.
Earnings released on 12 May 2022
EPS came in at -$5.76 surpassing the estimated -$5.88 by +2.04%.
Earnings released on 10 Mar 2022
EPS came in at -$4.92 surpassing the estimated -$6.00 by +18.00%.
Earnings released on 4 Nov 2021
EPS came in at -$4.92 surpassing the estimated -$6.60 by +25.45%, while revenue for the quarter reached $6.25M , missing expectations by -20.29%.
Earnings released on 5 Aug 2021
EPS came in at -$6.60 surpassing the estimated -$7.68 by +14.06%.
Earnings released on 6 May 2021
EPS came in at -$8.28 surpassing the estimated -$9.48 by +12.66%.
Earnings released on 25 Feb 2021
EPS came in at -$13.33 falling short of the estimated -$10.80 by -23.43%, while revenue for the quarter reached $1.04M , beating expectations by +7.14%.
Earnings released on 5 Nov 2020
EPS came in at -$1.08 surpassing the estimated -$9.36 by +88.46%, while revenue for the quarter reached $34.61M , missing expectations by -88.00%.
ASMB Stock Performance
Access detailed ASMB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.